-
FDA Grants De Novo Classification to neuropacs™, a First-in-Class AI-Based MRI Diagnostic Aid for Parkinsonian Syndromes
Multicenter Clinical Evidence Supports Use of neuropacs™ to Assist Clinicians in Differentiating Parkinsonian Syndromes, Strengthening Commercial Momentum GAINESVILLE, Fla.–(BUSINESS WIRE)–Neuropacs™ Corp., an innovator in AI-enabled neurological imaging, today announced that the U.S. Food and Drug Administration has granted De Novo classification to neuropacs™, a diffusion MRI–based software application designed to assist clinicians in the evaluation…
-
Neuropacs Closes Seed Round of Financing
Secures over $1.0M in Early-Stage Funding. GAINESVILLE, Fla.-neuropacs™ Corp., a leading innovator in AI-driven neurological diagnostics, announced today the successful raise of over $1.0 million in early-stage capital. Earlier last year, neuropacs hosted a private Investor event at the office of Mr. Richard A. Staab, a philanthropist and respected leader in the neurological and health-tech…
-
JAMA Neurology publishes landmark study showing neuropacs™ AI technology significantly enhances the diagnostic accuracy of Parkinson’s disease and atypical parkinsonism
NIH-funded clinical trial accelerates the launch of innovative software for Parkinson’s Disease diagnostic. GAINESVILLE, FL – neuropacsTM Corp., a leading innovator in AI-driven neurological diagnostics, announces the results of a prospective multicenter study that evaluated neuropacs™ AI technology for diagnosing Parkinson’s disease and atypical parkinsonism. The study was published in JAMA Neurology (doi: 10.1001/jamaneurol.2025.0112) and…
-
The journey of a typical patient suffering from Parkinson’s Disease
-
Automated Imaging Diagnostics Awarded Phase II Grant for Clinical Performance Testing of neuropacs™ in Parkinsonism Diagnosis
FOR IMMEDIATE RELEASE GAINESVILLE, FL. Automated Imaging Diagnostics (AID), a wholly-owned subsidiary of neuropacs Corp., a pioneering force in neurological diagnostic technologies, is thrilled to announce the awarding of a Small Business Technology Transfer (STTR) Phase II NIH NIA/NINDS grant to conduct a comprehensive pre-market field evaluation of its cutting-edge product, neuropacs™, specifically tailored for…
-
Revolutionary Alzheimer’s Diagnostic Technology Option Agreement Secured by neuropacs in Collaboration with UF
GAINESVILLE, FL – neuropacsTM, a leading innovator in medical diagnostics, is excited to announce the acquisition of an exclusive option agreement for a groundbreaking diagnostic technology for Alzheimer’s disease developed at the University of Florida. This innovative technology, spearheaded by neuropacsTM‘s Co-Founder and Chief Scientific Officer, David Vaillancourt, has the potential to revolutionize early detection…
-
Phase I STTR grant from NIH/NINDS to Enhance neuropacs Technology for Parkinsonism Classification
FOR IMMEDIATE RELEASE GAINESVILLE, FL. Automated Imaging Diagnostics, a leading innovator in medical technology, is proud to announce that its flagship product, neuropacsTM, has been awarded a Phase I Small Business Technology Transfer (STTR) grant from the National Institutes of Health, an NIH institute. This grant will drive forward the evolution of neuropacsTM and the…
-
Neuropacs Welcomes Dr. Jesse DeSimone as Director of Clinical and Business Development
GAINESVILLE, Fla. — Neuropacs™ Corp., a leader in AI-powered neurodiagnostics, today announced the appointment of Dr. Jesse DeSimone as Director of Clinical and Business Development. In this role, Dr. DeSimone will drive clinical evidence generation, commercial partnerships, and go-to-market strategy for Neuropacs’ suite of AI-powered imaging tools, advancing the company’s mission to improve diagnosis and…
-
Neuropacs Announces the Publication of a New Study Comparing the First‑of‑Its‑Kind FDA De Novo–Classified Imaging Biomarker for Parkinson’s Disease with CSF Alpha‑Synuclein Seed Amplification Assay
Research from the University of Florida, Mayo Clinic, and Vanderbilt University, in collaboration with the Parkinson’s Progression Markers Initiative, suggests that molecular and imaging biomarkers provide distinct information about Parkinson’s disease. GAINESVILLE, Fla.–(BUSINESS WIRE)–Neuropacs™ Corp., a leader in AI‑powered neurodiagnostics, today announced the publication of a seminal study co-authored by David Vaillancourt, PhD, the company’s…
-
Publication of a Breakthrough Study Demonstrating AI‑Enabled Diffusion MRI Can Accurately Differentiate Alzheimer’s Disease Dementia and Dementia with Lewy Bodies
AIDD: A New Imaging‑Based Approach to Dementia Differentiation GAINESVILLE, Fla. — Neuropacs™ Corp., a leader in AI‑powered neurodiagnostics, today announced the publication of a major new study led by David Vaillancourt, PhD, the company’s Co‑Founder and Chief Scientific Officer. The research published in Neurology Open Access introduces Automated Imaging Differentiation for Dementia (AIDD), a machine‑learning…
-
Neuropacs Appoints Dr. David R. Nelson to its Board of Advisors
Company secures a visionary health affairs leader for the launch of their innovative Parkinson’s diagnosis software. GAINESVILLE, FL – neuropacsTM, a leading innovator in AI-driven neurological diagnostics, today announced that David R. Nelson, MD has accepted to serve on neuropacs’ Board of Advisors, effective immediately. Dr. Nelson is the former Senior Vice President for Health…
Read more about Neuropacs Appoints Dr. David R. Nelson to its Board of Advisors
-
Neuropacs Welcomes Dr. Andrew Siderowf as a Member of its Board of Clinical Advisors
Company interfaces with a world-renowned clinician for the launch of their innovative software for the diagnostic of Parkinson’s Disease. GAINESVILLE, FL – neuropacsTM, a leading innovator in AI-driven neurological diagnostics, today announced that Andrew Siderowf, MD, MS , has accepted to serve on neuropacs’ Board of Clinical Advisors. Dr. Siderowf is the Hurtig-Stern Professor of…
Read more about Neuropacs Welcomes Dr. Andrew Siderowf as a Member of its Board of Clinical Advisors